This chapter describes the natural history of multiple sclerosis and, in particular, reviews the controversy regarding the entity of benign multiple sclerosis. Based on the Olmsted County population prevalence cohort study performed at the Mayo Clinic, MS patients with EDSS scores of 2 or lower followed for a period of 5–10 years have a very small risk of developing disability over the next 10–20 years. Based on these findings, this chapter reviews the indications, efficacy, mode of action, and side effect profiles of the currently approved and available diseasemodifying agents for the treatment of multiple sclerosis. The efficacy of these agents is discussed based on the concepts of evidence-based medicine and the natural history of the disease. We review the arguments for and against treating all patients with MS. The authors propose an individualized approach to the use of these agents in the MS population.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
The IFBN multiple sclerosis study group (1993) Interferon beta-1b is effective in relapsingremitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43:655-661
European study group in interferon beta-1b in secondary progressive MS (1998) placebocontrolled multicentre randomised trail of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 352:1491-1497
Amato M, Ponziani G (2000) A prospective study on the prognosis of multiple sclerosis. Neurol Sci 21:831-838
Bauer H, Firnhaber W, Winkler W (1965) Prognostic criteria in multiple sclerosis. Ann N Y Acad Sci 122:542-551
Brass S, Narayanan S, Antel J, Lapierre Y, Collins L, Arnold D (2004) Axonal damage in multiple sclerosis patients with high versus low expanded disability status scale score. Can J Neurol Sci 31:225-228
Charcot J (1872) Leçons sur les maladies du système nerveux faites à La Salpetière. In: Delahaye A, Lecrosnier E (eds) Progres Medicale, Paris
Cohen J, Cutter G, Fischer J, Goodman A, Heidenreich F, Kooijmans M, Sandrock A, Rudick R, Simon J, Simonian N, Tsao E, Whitaker J, IMPACT Investigators. (2002) Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology 59:679-686
Confavreux C, Aimard D, Devic M (1980) Course and prognosis of multiple sclerosis assessed by the computerised data processing of 349 patients. Brain 103:281-300
Confavreux C, Compston A (2005) The natural history of multiple sclerosis. In: Compston A, Confavreaux C, Lassmann H, McDonald I, Miller D, Noseworthy J et al., (eds) Mcalpine’s multiple sclerosis, 4th edn. Churchill Livingston, Philadelphia, pp 183-272
Confavreux C, Vukusic S, Adeleine P (2003) Early clinical predictors and progression of irreversible disability in multiple sclerosis: An amnesic process. Brain 126:770-782
Confavreux C, Vukusic S, Moreau T, Adeleine P (2000) Relapses and progression of disability in multiple sclerosis. N Engl J Med 343:1430-1438
Davie C, Silver N, Barker G, Tofts P, Thompson AJ, McDonald W, Miller D (1999) Does the extent of axonal loss and demyelination from chronic lesions in multiple sclerosis correlate with the clinical subgroup? J Neurol Neurosurg Psychiatry 67:710-715
De Stefano N, Battaglini M, Stromillo ML, Zipoli V, Bartolozzi ML, Guidi L, Siracusa G, Portaccio E, Giorgio A, Sorbi S, Federico A, Amato MP (2006) Brain damage as detected by magnetization transfer imaging is less pronounced in benign than in early relapsing multiple sclerosis. Brain 129:2008-2016
Eriksson M, Andersen O, Runmarker B (2003) Long-term follow-up of patients with clinically isolated syndromes, relapsing-remitting and secondary progressive multiple sclerosis. Mult Scler 9:260-274
Falini A, Calabrese G, Filippi M, Origgi D, Lipari S, Colombo B, Comi G, Scotti G (1998) Benign versus secondary-progressive multiple sclerosis: The potential role of proton MR spectroscopy in defining the nature of disability. ANJR Am J Neuroradiol 19:223-229
Filippi M, Campi A, Mammi S, Martinelli V, Locatelli T, Scotti G, Amadio S, Canal N, Comi G (1995) Brain magnetic resonance imaging and multimodal evoked potentials in benign and secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 58:31-37
Filippi M, Campi A, Mammi S, Sacares P, MacManus D, Thompson A, Tofts P, McDonald W, Miller D (1994) Benign and secondary progressive multiple sclerosis: A preliminary quantitative MRI study. J Neurol 241:246-251
Filippi M, Inglese M, Rovaris M, Sormani M, Horsfield M, Iannucci P, Colombo B, Comi G (2000) Magnetization transfer imaging to monitor the evolution of MS: A 1-year follow-up study. Neurology 55:940-946
Fog T, Linnemann F (1970) The course of multiple sclerosis in 73 cases with computerdesigned curves. Acta Neurol Scand 46:1-175
Francis G (2004) Importance of benefit-to-risk assessment for disease-modifying drugs used to treat MS. J Neurol 251:V42-V49
Frohman E, Havrdova E, Lublin F, Barkhof F, Achiron A, Sharief M, Stuve O, Racke M, Steinman L, Weiner H, Olek M, Zivadinov R, Corboy J, Raine C, Cutter G, Richert J, Filippi M (2006) Most patients with multiple sclerosis or a clinically isolated demyelinating syndrome should be treated at the time of diagnosis. Arch Neurol 63:614-619
Goodkin D, Hertsgaard D (2000) Seasonal variation of multiple sclerosis exacerbations in North Dakota. Arch Neurol 46:1015-1018
Hartung H, Gonsette R, Konig N, Kwiecinski H, Guseo A, Morrissey S, Krapf H, Zwingers T (2002) Mitoxantrone in progressive multiple sclerosis: A placebo-controlled, double-blind, randomised, multicentre trial. Lancet 360(9350):2018-2025
Hawkins S, McDonnella G (1999) Benign multiple sclerosis? Clinical course, long term follow up, and assessment of prognostic factors. J Neurol Neurosurg Psychiatry 67:148-152
Horsfield M, Lai M, Webb S, Barker G, Tofts P, Turner R, Rudge P, Miller D (1996) Apparent diffusion coefficients in benign and secondary progressive multiple sclerosis by nuclear magnetic resonance. Magn Reson Med 36:393-400
Johnson K, Brooks B, Cohen J, Ford C, Goldstein J, Lisak R, Myers L, Panitch H, Rose J, Schiffer R, Vollmer T, Weiner L, Wolinsky J (1995) Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 45:1268-1276
Johnson K, Brooks B, Ford C, Goodman A, Guarnaccia J, Lisak R, Myers L, Panitch H, Pruitt A, Rose J, Kachuck N, Wolinsky J (2000) Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 multiple sclerosis study group. Mult Scler 6:255-266
Kantarci O, De Andrade M, Weinshenker B (2002) Identifying disease modifying genes in multiple sclerosis. J Neuroimmunol 123:144-159
Kantarci O, Siva A, Eraksoy M, Karabudak R, Sutlas N, Agaoglu J, Turan F, Ozmenoglu M, Togrul E, Demirkiran M (1998) Survival and predictors of disability in Turkish MS patients. Turkish Multiple Sclerosis Study Group (TUMSSG). Neurology 51:765-772
Kappos L, Clanet M, Sandberg-Wollheim M, Radue E, Hartung H, Hohlfeld R, Xu J, Bennett D, Sandrock A, Goelz S (2005) Neutralizing antibodies and efficacy of interferon beta-1a: A 4-year controlled study. Neurology 65:40-47
Kermode AG, Tofts PS, Thompson AJ, MacManus DG, Rudge P, Kendall BE, Kingsley DP, Moseley IF, du Boulay EP, McDonald WI (1990) Heterogeneity of blood-brain barrier changes in multiple sclerosis: An MRI study with gadolinium-DTPA enhancement. Neurology 40:229-235
Kinkel R (2006) Im interferon β-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology 66:678-684
Koopman R, Li D, Grochowsky E, Cutler P, Paty D (1989) Benign versus chronic progressive multiple sclerosis: Magnetic resonance imaging features. Ann Neurol 25:74-81
Kurtzke J (1977) Geography in multiple sclerosis. J Neurol 215:1-26
Kurtzke J (1983) Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 33:1444-1452
Kurtzke J, Beebe G, Nagler B, Auth T, Kurland L, Nefzger M (1968) Studies on natural history of multiple sclerosis. 4: Clinical features of the onset bout. Acta Neurol Scand 44:467-499
Kurtzke J, Beebe G, Nagler B, Nefzger M, Auth T, Kurland L (1970) Studies on the natural history of multiple sclerosis 5: Long-term survival in young men. Arch Neurol 22:215-225
Langer-Gould A, Popat R, Huang S, Cobb K, Fontoura P, Gould M (2006) Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis. Arch Neurol 63:1686-1691
Leibowitz U, Alter M (1970) Clinical factors associated with increased disability in multiple sclerosis. Acta Neurol Scand 46:53-70
Leibowitz U, Alter M (1973) Multiple sclerosis: Clues to its cause. Amsterdam: North Holland
Li D, Zhao G, Paty D, University of British Columbia MS/MRI Analysis Research Group, SPECTRIMS Study Group (2001) Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results. Neurology 56:1505-1513
Lublin F, Reingold S (1996) The national multiple sclerosis society USA advisory committee on clinical trails of new agents in multiple sclerosis. Defining the clinical course of multiple sclerosis: Results of an international survey. Neurology 46:907-911
McAlpine D (1964) The benign form of multiple sclerosis: Results of a long-term study. BMJ 2:1029-1032
McAlpine D, Compston N (1952) Some aspects of the natural history of disseminated sclerosis. Q J Med 21:135-167
Minneboo A, Uitdehaag B, Ader H, Barkhof F, Polman C, Castelijins J (2005) Patterns of enhancing lesion evolution in multiple sclerosis are uniform within patients. Neurology 65:56-61
Myhr K, Riise T, Vedeler C, Nortvedt MW, Gronning R, Midgard R, Nyland HI (2001) Disability and prognosis in multiple sclerosis: demographic and clinical variables important for the ability to walk and awarding of disability pension. Mult Scler 7:59-65
Noseworthy J, Miller D, Compston A (2005) Disease-modifying treatments in multiple sclerosis. Churchill Livingston, London, pp 729-802
Patzold U, Pocklington P (1982) Course of multiple sclerosis: Results of a prospective study carried out of 102 MS patients from 1976-1980. Acta Neurol Scand 65:248-266
Pittock S (2007) Does benign MS today imply benign MS tomorrow? Implications for treatment. Neurology 68:480-481
Pittock S, Mayr W, McClelland R, Jorgensen N, Weigand S, Noseworthy J, Rodriguez M (2004) Disability profile of MS did not change over 10 years in a population-based prevalence cohort. Neurology 62:601-606
Pittock S, Mayr W, McClelland R, Jorgensen N, Weigand S, Noseworthy J, Weinshenker B, Rodriguez M (2004) Change in MS-related disability in a population-based cohort: A 10-year follow-up study. Neurology 62:51-59
Pittock S, McClelland R, Mayr W, Jorgensen N, Weinshenker B, Noseworthy J, Rodriguez M (2004) Clinical implications of benign multiple sclerosis: A 20-year population-based followup study. Ann Neurol 56:303-306
Pittock S, Noseworthy J, Rodriguez M (2007) MRI findings in benign multiple sclerosis are variable. J Neurol 254:539-541
Pittock S, Weinshenker B, Noseworthy J, Lucchinetti C, Keegan M, Wingerchuk D, Carter J, Shuster E, Rodriguez M (2006) Not every patient with multiple sclerosis should be treated at time of diagnosis. Arch Neurol 63:611-614
Polman C, O’Connor P, Havrdova E, Hutchinson M, Kappos L, Miller D, Phillips J, Lublin F, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara M, Sandrock A (2006) A randomized, placebocontrolled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354:899-910
Ramsaransing G, De Keyser J (2006) Benign course in multiple sclerosis: A review. Acta Neurol Scand 113:359-369
Rodriguez M, Siva A, Cross S, Stolp-Smith K, O’Brien P, Kurland L (1994) Impairment, disability, and handicap in multiple sclerosis: A population-based study in Olmsted county, Minnesota. Neurology 44:28-33
Runmarker B, Andersen O (1993) Prognostic factors in multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain 116:117-134
Sayao A, Devonshire V, Tremlett H (2007) Longitudinal follow-up of ‘benign’ multiple sclerosis at 20 years. Neurology 68:480-481
SPECTRIMS Study Group HR (2001) Randomized controlled trial of interferon-beta-1a in secondary progressive ms: Clinical results. Neurology 56:1496-1504
Thompson A (1999) Benign multiple sclerosis. J Neurol Neurosurg Psychiatry 67:138
Thompson A, Kermode A, MacManus D, Kendall BE, Kingsley DP, Moseley IF, McDonald WI (1990) Patterns of disease activity in multiple sclerosis: Clinical and magnetic resonance imaging study. BMJ 300:631-634
Thompson AJ, Miller D, Youl B, MacManus D, Moore S, Kingsley D, Kendall B, Feinstein A, Mcdonald WI (1992) Serial gadolinium-enhanced MRI in relapsing/remitting multiple sclerosis of varying disease duration. Neurology 42:60-62
Traboulsee A, Dehmeshki J, Peters K, Griffin C, Brex P, Silver N, Ciccarrelli O, Chard D, Barker G, Thompson A, Miller D (2003) Disability in multiple sclerosis is related to normal appearing brain tissue MTR histogram abnormalities. Mult Scler 9:566-573
Tremlett H, Paty D, Devonshire V (2005) Disability progression in multiple sclerosis is slower than previously reported. Neurology 66:172-177
van Waesberghe J, Walderveen M, Castelijins J, Scheltens P, Nijeholt G, Polman C, Barkof F (1998) Patterns of lesion development in multiple sclerosis: Longitudinal observations with t1-weighted spin-echo and magnetization transfer MR. AJNR Am J Neuroradiol 19:675-683
Weinshenker B, Bass B, Rice G (1989a) The natural history of multiple sclerosis: A geographically based study. 1. Clinical course and disability. Brain 112:133-146
Weinshenker B, Bass B, Rice G, Noseworthy J, Carriere W, Baskerville J, Ebers G (1989b) The natural history of multiple sclerosis: A geographically based study. 2. Predictive value of the early clinical course. Brain 112:133-146
Weinshenker B, Rice G, Noseworthy J, Carriere W, Baskerville J, Ebers G (1991) The natural history of multiple sclerosis: A geographically based study. 3. Multivariate analysis of predictive factors and models of outcome. Brain 114:1045-1056
Wingerchuk D (2006) Multiple sclerosis disease-modifying therapies: Adverse effect surveillance and management. Expert Rev Neurotherapeutics 6:333-346
Yousry T, Major E, Ryschkewitsch C, Fahle G, Fischer S, Hou J, Curfman B, Miszkiel K, Mueller-Lenke N, Sanchez E, Barkhof F, Radue E, Jager H, Clifford D (2006) Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 354:924-933
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Pittock, S.J., Rodriguez, M. (2008). Benign Multiple Sclerosis: A Distinct Clinical Entity with Therapeutic Implications. In: Rodriguez, M. (eds) Advances in multiple Sclerosis and Experimental Demyelinating Diseases. Current Topics in Microbiology and Immunology, vol 318. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-73677-6_1
Download citation
DOI: https://doi.org/10.1007/978-3-540-73677-6_1
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-73676-9
Online ISBN: 978-3-540-73677-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)